1Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Kangdong Sacred Heart Hospital, Seoul, Korea
2Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
3Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
Copyright © 2020 The Korean Society of Critical Care Medicine
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
CONFLICT OF INTEREST No potential conflict of interest relevant to this article was reported.
AUTHOR CONTRIBUTIONS
Conceptualization: JL, JC. Data curation: YJL. Formal analysis: YJL. Methodology: YJL, SML, JL. Project administration: SML, JL. Visualization: YJL. Writing–original draft: YJL. Writing–review and editing: JC, SML, JL.
| Patient no. | Age (yr) | Sex | BMI (kg/m2) |
Symptom |
Neck circumference (cm) | STOP-Bang score | Comorbidity | APACHE II score | Duration of mechanical ventilation (day) | Reason for mechanical ventilation | In-hospital outcome | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EDS | Nonrestorative sleep | Fatigue | Insomnia | Snoring | Witnessed apnea | |||||||||||
| 1a | 77 | M | 21.7 | - | - | - | - | - | - | - | - | HTN, DM, multiple myeloma | 35 | 7 | Sepsis | Died 14 days after ICU discharge |
| 2 | 56 | F | 21.7 | No | Yes | Yes | No | Yes | No | 37.0 | 2 | DM, post-lung TPL | 21 | 2 | Pneumonia | Survived |
| 3 | 58 | M | 26.2 | No | Yes | Yes | No | No | No | 39.0 | 3 | Sarcoma | 22 | 8 | Pneumonia | Survived |
| 4 | 80 | M | 27.4 | No | No | No | No | No | No | 42.0 | 3 | DM, CHF, CVD, AF, lung cancer | 13 | 6 | Pneumonia | Survived |
| 5 | 67 | M | 20.8 | No | No | Yes | Yes | No | No | 38.5 | 3 | CHF, AF, COPD, LC | 25 | 6 | CHF | Survived |
| 6 | 83 | M | 14.3 | No | No | No | No | No | No | 38.0 | 2 | NTM-PD | 18 | 4 | Pneumonia | Died 237 days after ICU discharge |
| 7 | 70 | M | 28.7 | No | Yes | Yes | No | Yes | Yes | 43.0 | 6 | Post-lung TPL | 15 | 3 | Post-lung TPL | Survived |
| 8 | 75 | M | 25.5 | No | No | No | No | No | No | 45.0 | 3 | IPF, vasculitis | 35 | 8 | Pneumonia | Died 13 days after ICU discharge |
| 9 | 69 | F | 24.9 | Yes | Yes | Yes | Yes | Yes | Yes | 40.0 | 5 | OSA, asthma | 20 | 5 | Acute exacerbation of asthma | Survived |
| 10 | 74 | M | 22.5 | Yes | Yes | Yes | No | No | No | 38.0 | 3 | Asthma, COPD, CKD, leiomyosarcoma | 30 | 3 | Pneumonia | Died 19 days after ICU discharge |
BMI: body mass index; EDS: excessive daytime sleepiness; STOP-Bang: snoring, tiredness, observed apnea, high blood pressure, body mass index, age, neck circumference, and gender; APACHE: Acute Physiology and Chronic Health Evaluation; HTN: hypertension; DM: diabetes mellitus; ICU: intensive care unit; TPL: transplantation; CHF: congestive heart failure; CVD: cardiovascular disease; AF: atrial fibrillation; COPD: chronic obstructive pulmonary disease; LC: liver cirrhosis; NTM-PD: nontuberculous mycobacterial pulmonary disease; IPF: idiopathic pulmonary fibrosis; OSA: obstructive sleep apnea; CKD: chronic kidney disease.
aPatient 1 had missing data regarding symptoms, neck circumference, and STOP-Bang score.
| Variable | All patients (n=10) | Patient with an REI <5/hr (n=7) | Patient with an REI ≥5/hr (n=3) |
|---|---|---|---|
| Age (yr) | 72 (67–77) | 74 (67–77) | 69 (56–83) |
| Male sex | 8 (80) | 7 (100) | 1 (33) |
| BMI (kg/m2) | 23.7 (21.7–26.2) | 25.5 (21.7–27.4) | 21.7 (14.3–24.9) |
| Neck circumference (cm)a | 39 (38–42) | 41 (39–43) | 38 (37–40) |
| STOP-Bang score ≥3a | 7 (70) | 6 (86) | 1 (33) |
| Charlson comorbidity index | 5 (3–8) | 6 (5–8) | 2 (0–3) |
| Hypertension | 1 (10) | 1 (14) | 0 |
| Diabetes | 3 (30) | 2 (29) | 1 (33) |
| Congestive heart failure | 2 (20) | 2 (29) | 0 |
| COPD | 2 (20) | 2 (29) | 0 |
| APACHE II score | 22 (18–30) | 25 (15–35) | 20 (18–21) |
| SOFA score | 6 (5–10) | 9 (4–10) | 5 (5–7) |
| SAPS II | 48 (32–66) | 54 (32–68) | 46 (30–50) |
| Failure during the first intubation attempt | 4 (40) | 3 (43) | 1 (33) |
| Internal diameter of the endotracheal tubes (mm) | 7.5 (7.5–7.5) | 7.5 (7.5–7.5) | 7.5 (7.0–7.5) |
| Duration of mechanical ventilation (day) | 6 (3–7) | 6 (3–8) | 4 (2–5) |
| Reason for mechanical ventilation | |||
| Pneumonia | 6 (60) | 4 (57) | 2 (67) |
| Acute exacerbation of asthma | 1 (10) | 0 | 1 (33) |
| Heart failure | 1 (10) | 1 (14) | 0 |
| Sepsis | 1 (10) | 1 (14) | 0 |
| Post-lung transplantation | 1 (10) | 1 (14) | 0 |
| Total drug equivalent dose administered 48 hours prior to extubation | |||
| Remifentanyl (mg) | 7.4 (4.2–10.6) | 9.6 (4.2–22.1) | 4.8 (1.8–9.6) |
| Propofol (mg) | 0 (0–1,344) | 0 (0–1,728) | 0 (0–1,344) |
| Dexmedetomidine (mg) | 1.1 (0.04–3.0) | 0.8 (0.04–3.6) | 1.5 (0–3.0) |
| Methylprednisolone (mg) | 78 (0–120) | 60 (0–160) | 100 (0–120) |
| Method of oxygen delivery during the night of respiratory polygraphy | |||
| Low-flow oxygen therapy via nasal prong | 5 (50) | 2 (29) | 3 (100) |
| High-flow nasal cannula | 5 (50) | 5 (71) | 0 |
| FiO2 | 0.4 (0.3–0.5) | 0.4 (0.4–0.6) | 0.3 (0.3–0.4) |
| Flow (L/min) | 23 (2–60) | 40 (4–60) | 2 (2–6) |
Values are presented as median (interquartile range) or number (%).
REI: respiratory event index; BMI: body mass index; STOP-Bang: snoring, tiredness, observed apnea, high blood pressure, body mass index, age, neck circumference, and gender; COPD: chronic obstructive pulmonary disease; APACHE: Acute Physiology and Chronic Health Evaluation; SOFA: Sequential Organ Failure Assessment; SAPS: Simplified Acute Physiology Score; FiO2: fraction of inspired oxygen.
aPatient 1 had missing data regarding neck circumference and STOP-Bang score.
| Patient no. |
Total drug equivalent dose administered 48 hours prior to extubation |
Method of oxygen delivery during the night of respiratory polygraphy |
REI (/hr) | Mean SpO2 (%) | Lowest SpO2 (%) | Time spent (%) with SpO2 <90% | ODI (/hr) | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Remifentanyl (mg) | Propofol (mg) | Dexmedetomidine (mg) | Methylprednisolone (mg)a | Device | Flow rate (L/min) | FiO2 of HFNC | ||||||
| 1 | 5.3 | 0 | 2.9 | 0 | Low-flow via nasal prong | 4 | – | 1.1 | 92 | 83 | 5.9 | 3.5 |
| 2 | 1.8 | 0 | 3.0 | 100 | Low-flow via nasal prong | 6 | – | 7.5 | 97 | 74 | 1.0 | 8.1 |
| 3 | 10.6 | 0 | 0.7 | 160 | HFNC | 60 | 0.6 | 2.1 | 93 | 85 | 1.5 | 2.0 |
| 4 | 9.6 | 0 | 2.0 | 60 | HFNC | 60 | 0.4 | 0.3 | 93 | 86 | 4.4 | 0.3 |
| 5 | 2.0 | 0 | 0.04 | 0 | Low-flow via nasal prong | 2 | – | 0.8 | 98 | 86 | 0.2 | 1.8 |
| 6 | 4.8 | 0 | 1.5 | 0 | Low-flow via nasal prong | 2 | – | 8.8 | 97 | 87 | 0.3 | 5.0 |
| 7 | 22.1 | 4,722 | 0.8 | 250 | HFNC | 40 | 0.4 | 0.1 | 93 | 87 | 1.8 | 0.1 |
| 8 | 26.4 | 0 | 3.6 | 96 | HFNC | 60 | 0.5 | 0.1 | 94 | 88 | 0.2 | 0.3 |
| 9 | 9.6 | 1,344 | 0 | 120 | Low-flow via nasal prong | 2 | – | 7.7 | 92 | 75 | 13.3 | 14.7 |
| 10 | 4.2 | 1,728 | 0 | 40 | HFNC | 40 | 0.6 | 0.4 | 90.8 | 82 | 19.4 | 1.5 |
FiO2: fraction of inspired oxygen; HFNC: high-flow nasal cannula; REI: respiratory event index; SpO2: oxygen saturation; ODI: oxygen desaturation index.
aSix of the seven patients who were treated with corticosteroids received methylprednisolone intravenously. Patient 10 received 50 mg hydrocortisone intravenously four times for 48 hours prior to extubation. Five of the seven patients who received corticosteroids were treated with long-term corticosteroid therapy. The remaining two patients, patients 4 and 10, were treated with corticosteroids for 15 days and 2 days, respectively.
| Patient no. | Age (yr) | Sex | BMI (kg/m2) | Symptom |
Neck circumference (cm) | STOP-Bang score | Comorbidity | APACHE II score | Duration of mechanical ventilation (day) | Reason for mechanical ventilation | In-hospital outcome | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EDS | Nonrestorative sleep | Fatigue | Insomnia | Snoring | Witnessed apnea | |||||||||||
| 1 |
77 | M | 21.7 | - | - | - | - | - | - | - | - | HTN, DM, multiple myeloma | 35 | 7 | Sepsis | Died 14 days after ICU discharge |
| 2 | 56 | F | 21.7 | No | Yes | Yes | No | Yes | No | 37.0 | 2 | DM, post-lung TPL | 21 | 2 | Pneumonia | Survived |
| 3 | 58 | M | 26.2 | No | Yes | Yes | No | No | No | 39.0 | 3 | Sarcoma | 22 | 8 | Pneumonia | Survived |
| 4 | 80 | M | 27.4 | No | No | No | No | No | No | 42.0 | 3 | DM, CHF, CVD, AF, lung cancer | 13 | 6 | Pneumonia | Survived |
| 5 | 67 | M | 20.8 | No | No | Yes | Yes | No | No | 38.5 | 3 | CHF, AF, COPD, LC | 25 | 6 | CHF | Survived |
| 6 | 83 | M | 14.3 | No | No | No | No | No | No | 38.0 | 2 | NTM-PD | 18 | 4 | Pneumonia | Died 237 days after ICU discharge |
| 7 | 70 | M | 28.7 | No | Yes | Yes | No | Yes | Yes | 43.0 | 6 | Post-lung TPL | 15 | 3 | Post-lung TPL | Survived |
| 8 | 75 | M | 25.5 | No | No | No | No | No | No | 45.0 | 3 | IPF, vasculitis | 35 | 8 | Pneumonia | Died 13 days after ICU discharge |
| 9 | 69 | F | 24.9 | Yes | Yes | Yes | Yes | Yes | Yes | 40.0 | 5 | OSA, asthma | 20 | 5 | Acute exacerbation of asthma | Survived |
| 10 | 74 | M | 22.5 | Yes | Yes | Yes | No | No | No | 38.0 | 3 | Asthma, COPD, CKD, leiomyosarcoma | 30 | 3 | Pneumonia | Died 19 days after ICU discharge |
| Variable | All patients (n=10) | Patient with an REI <5/hr (n=7) | Patient with an REI ≥5/hr (n=3) |
|---|---|---|---|
| Age (yr) | 72 (67–77) | 74 (67–77) | 69 (56–83) |
| Male sex | 8 (80) | 7 (100) | 1 (33) |
| BMI (kg/m2) | 23.7 (21.7–26.2) | 25.5 (21.7–27.4) | 21.7 (14.3–24.9) |
| Neck circumference (cm) |
39 (38–42) | 41 (39–43) | 38 (37–40) |
| STOP-Bang score ≥3 |
7 (70) | 6 (86) | 1 (33) |
| Charlson comorbidity index | 5 (3–8) | 6 (5–8) | 2 (0–3) |
| Hypertension | 1 (10) | 1 (14) | 0 |
| Diabetes | 3 (30) | 2 (29) | 1 (33) |
| Congestive heart failure | 2 (20) | 2 (29) | 0 |
| COPD | 2 (20) | 2 (29) | 0 |
| APACHE II score | 22 (18–30) | 25 (15–35) | 20 (18–21) |
| SOFA score | 6 (5–10) | 9 (4–10) | 5 (5–7) |
| SAPS II | 48 (32–66) | 54 (32–68) | 46 (30–50) |
| Failure during the first intubation attempt | 4 (40) | 3 (43) | 1 (33) |
| Internal diameter of the endotracheal tubes (mm) | 7.5 (7.5–7.5) | 7.5 (7.5–7.5) | 7.5 (7.0–7.5) |
| Duration of mechanical ventilation (day) | 6 (3–7) | 6 (3–8) | 4 (2–5) |
| Reason for mechanical ventilation | |||
| Pneumonia | 6 (60) | 4 (57) | 2 (67) |
| Acute exacerbation of asthma | 1 (10) | 0 | 1 (33) |
| Heart failure | 1 (10) | 1 (14) | 0 |
| Sepsis | 1 (10) | 1 (14) | 0 |
| Post-lung transplantation | 1 (10) | 1 (14) | 0 |
| Total drug equivalent dose administered 48 hours prior to extubation | |||
| Remifentanyl (mg) | 7.4 (4.2–10.6) | 9.6 (4.2–22.1) | 4.8 (1.8–9.6) |
| Propofol (mg) | 0 (0–1,344) | 0 (0–1,728) | 0 (0–1,344) |
| Dexmedetomidine (mg) | 1.1 (0.04–3.0) | 0.8 (0.04–3.6) | 1.5 (0–3.0) |
| Methylprednisolone (mg) | 78 (0–120) | 60 (0–160) | 100 (0–120) |
| Method of oxygen delivery during the night of respiratory polygraphy | |||
| Low-flow oxygen therapy via nasal prong | 5 (50) | 2 (29) | 3 (100) |
| High-flow nasal cannula | 5 (50) | 5 (71) | 0 |
| FiO2 | 0.4 (0.3–0.5) | 0.4 (0.4–0.6) | 0.3 (0.3–0.4) |
| Flow (L/min) | 23 (2–60) | 40 (4–60) | 2 (2–6) |
| Patient no. | Total drug equivalent dose administered 48 hours prior to extubation |
Method of oxygen delivery during the night of respiratory polygraphy |
REI (/hr) | Mean SpO2 (%) | Lowest SpO2 (%) | Time spent (%) with SpO2 <90% | ODI (/hr) | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Remifentanyl (mg) | Propofol (mg) | Dexmedetomidine (mg) | Methylprednisolone (mg) |
Device | Flow rate (L/min) | FiO2 of HFNC | ||||||
| 1 | 5.3 | 0 | 2.9 | 0 | Low-flow via nasal prong | 4 | – | 1.1 | 92 | 83 | 5.9 | 3.5 |
| 2 | 1.8 | 0 | 3.0 | 100 | Low-flow via nasal prong | 6 | – | 7.5 | 97 | 74 | 1.0 | 8.1 |
| 3 | 10.6 | 0 | 0.7 | 160 | HFNC | 60 | 0.6 | 2.1 | 93 | 85 | 1.5 | 2.0 |
| 4 | 9.6 | 0 | 2.0 | 60 | HFNC | 60 | 0.4 | 0.3 | 93 | 86 | 4.4 | 0.3 |
| 5 | 2.0 | 0 | 0.04 | 0 | Low-flow via nasal prong | 2 | – | 0.8 | 98 | 86 | 0.2 | 1.8 |
| 6 | 4.8 | 0 | 1.5 | 0 | Low-flow via nasal prong | 2 | – | 8.8 | 97 | 87 | 0.3 | 5.0 |
| 7 | 22.1 | 4,722 | 0.8 | 250 | HFNC | 40 | 0.4 | 0.1 | 93 | 87 | 1.8 | 0.1 |
| 8 | 26.4 | 0 | 3.6 | 96 | HFNC | 60 | 0.5 | 0.1 | 94 | 88 | 0.2 | 0.3 |
| 9 | 9.6 | 1,344 | 0 | 120 | Low-flow via nasal prong | 2 | – | 7.7 | 92 | 75 | 13.3 | 14.7 |
| 10 | 4.2 | 1,728 | 0 | 40 | HFNC | 40 | 0.6 | 0.4 | 90.8 | 82 | 19.4 | 1.5 |
BMI: body mass index; EDS: excessive daytime sleepiness; STOP-Bang: snoring, tiredness, observed apnea, high blood pressure, body mass index, age, neck circumference, and gender; APACHE: Acute Physiology and Chronic Health Evaluation; HTN: hypertension; DM: diabetes mellitus; ICU: intensive care unit; TPL: transplantation; CHF: congestive heart failure; CVD: cardiovascular disease; AF: atrial fibrillation; COPD: chronic obstructive pulmonary disease; LC: liver cirrhosis; NTM-PD: nontuberculous mycobacterial pulmonary disease; IPF: idiopathic pulmonary fibrosis; OSA: obstructive sleep apnea; CKD: chronic kidney disease. Patient 1 had missing data regarding symptoms, neck circumference, and STOP-Bang score.
Values are presented as median (interquartile range) or number (%). REI: respiratory event index; BMI: body mass index; STOP-Bang: snoring, tiredness, observed apnea, high blood pressure, body mass index, age, neck circumference, and gender; COPD: chronic obstructive pulmonary disease; APACHE: Acute Physiology and Chronic Health Evaluation; SOFA: Sequential Organ Failure Assessment; SAPS: Simplified Acute Physiology Score; FiO2: fraction of inspired oxygen. Patient 1 had missing data regarding neck circumference and STOP-Bang score.
FiO2: fraction of inspired oxygen; HFNC: high-flow nasal cannula; REI: respiratory event index; SpO2: oxygen saturation; ODI: oxygen desaturation index. Six of the seven patients who were treated with corticosteroids received methylprednisolone intravenously. Patient 10 received 50 mg hydrocortisone intravenously four times for 48 hours prior to extubation. Five of the seven patients who received corticosteroids were treated with long-term corticosteroid therapy. The remaining two patients, patients 4 and 10, were treated with corticosteroids for 15 days and 2 days, respectively.